HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

Capricor Therapeutics plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Good Morning Britain presenter Ranvir Singh has opened up about her secret health battle and has revealed the special way ...